MHRA GLP Compliance Programme MemberLast inspected March 2025

UKAS Accredited to ISO/IEC 17025UKAS Testing Laboratory No. 8821

Home Office Controlled Drugs Licence

HTA licencenot required for routine blood/plasma/urine bioanalysis

Alderley Park · GLP bioanalysis since 2012

Regulated bioanalysis, published as a datasheet not a brochure.

Laboratory scientist

MHRA GLP Compliance Programme member and UKAS ISO/IEC 17025 accredited. LC-MS/MS and ligand-binding bioanalysis with a QA unit fully independent of study conduct.

On the datasheet

  • 01MHRA GLP Compliance Programme member
  • 02UKAS accredited to ISO/IEC 17025
  • 03Method validation to ICH M10 (2022)
  • 04QA unit independent of study conduct

Methods

Five assays, specified in full

Analyte, matrix, platform and validated range for each method. The validation report carries the precision and accuracy data.

  • LC-MS/MS Small Molecule Bioanalysis

    01
    Analyte
    Small-molecule drug & metabolite
    Matrix
    Plasma, serum, urine
    Platform
    LC-MS/MS (triple-quadrupole)
    LLOQ
    Low pg/mL–ng/mL, analyte-dependent
    Validated
    ICH M10 (2022)
  • Ligand-Binding Assays (LBA)

    02
    Analyte
    Large-molecule therapeutic / biomarker
    Matrix
    Serum, plasma
    Platform
    ELISA / electrochemiluminescence
    LLOQ
    Assay-dependent, fixed at validation
    Validated
    ICH M10, large-molecule provisions
  • PK/TK Study Bioanalysis

    03
    Analyte
    Study-defined PK/TK analyte
    Matrix
    Per study protocol
    Platform
    LC-MS/MS or LBA, per method
    LLOQ
    Per validated method
    Validated
    GLP or non-GLP, per study
  • Immunogenicity Testing (ADA/NAb)

    04
    Analyte
    Anti-drug antibody (ADA) / NAb
    Matrix
    Serum, plasma
    Platform
    Tiered screen / confirm / titre
    LLOQ
    Cut-point set per assay
    Validated
    Tiered strategy, current guidance
  • Method Development & Validation

    05
    Analyte
    Novel analyte / bespoke matrix
    Matrix
    Study-defined
    Platform
    Developed from first principles
    LLOQ
    Established during development
    Validated
    Full ICH M10 on completion

Services

Everything we run

Typical prices, set out before a study starts.

  1. 01LC-MS/MS Small Molecule BioanalysisFrom £8,400

    Quantitative small-molecule bioanalysis by LC-MS/MS, validated to ICH M10, LLOQ down to pg/mL. typical full method validation, small molecule

  2. 02Ligand-Binding Assays (LBA)From £11,200

    Ligand-binding assay development and validation for large-molecule and biomarker quantification. typical full method validation, ligand-binding assay

  3. 03PK/TK Study BioanalysisFrom £95

    Sample analysis support for pharmacokinetic and toxicokinetic studies, GLP and non-GLP. per sample, volume-dependent, from

  4. 04Immunogenicity Testing (ADA/NAb)From £13,500

    Anti-drug antibody and neutralising antibody assay development for biologics immunogenicity assessment. typical tiered ADA assay development

  5. 05Method Development & ValidationFrom £6,500

    Bespoke bioanalytical method development where no validated method exists for a novel analyte or matrix. scoped fixed fee, method development

  6. 06Sample Management & StorageFrom £4

    Chain-of-custody sample receipt, -80°C storage and controlled-drugs handling under Home Office licence. per sample, per month storage, from

  7. 07GLP Study Reporting & QA AuditFrom £2,800

    Full GLP study reporting with independent QA unit audit at defined study milestones. GLP study reporting and QA audit, typical study

Record

Years running GLP bioanalytical studies
13
Validated bioanalytical methods on file
340+
Typical turnaround, working days, from sample receipt
15
Studies with QA unit independent of conduct
100%

Study lifecycle

Five stages in order.

  1. 01

    Feasibility & scoping

    We assess the analyte, matrix and regulatory context before quoting a method development or validation scope.

  2. 02

    Method development

    A bespoke or platform method is developed and pre-validated against ICH M10 criteria.

  3. 03

    Full validation

    Full method validation is completed and a validation report issued ahead of sample analysis.

  4. 04

    Sample analysis

    Study samples are analysed against the validated method, tracked against the agreed turnaround.

  5. 05

    QA audit & reporting

    The independent QA unit audits protocol, raw data and final report before issue to the sponsor.

Laboratory

Where the work happens

  • Research laboratory testing
    01Sample receiptChain-of-custody sample receipt and logging.
  • Lab technician microscope
    02Ligand-binding assay benchELISA plate work for a large-molecule bioanalytical method.
  • Laboratory scientist
    03Method developmentDeveloping and pre-validating a method against ICH M10 criteria.
  • Bioanalytical lab equipment
    04LC-MS/MS suiteTriple-quadrupole LC-MS/MS instrumentation in the Alderley Park laboratory.
  • Scientist pipette lab
    05Sample preparationSample preparation ahead of analysis under the GLP quality system.
  • Research laboratory testing
    06Sample analysisStudy samples analysed against the validated method.

Sponsors

What Alderley Park says

The validation report gave us the full precision and accuracy dataset, not a one-line summary. Our regulatory submission team could use it directly.

Dr. Helen MarchettiCambridge · Head of Bioanalysis, a mid-size pharmaceutical sponsor

Having a QA unit that genuinely reports outside the study team's line management made a difference during our own sponsor audit, the inspectors noticed.

Dr. Ravi ChandrasekaranMacclesfield · Director of Clinical Pharmacology, biotech sponsor

We needed a bespoke method for an unusual matrix at short notice. Alderwood scoped and quoted it in two days rather than the two weeks we'd been quoted elsewhere.

Dr. Fiona WhitlockManchester · Preclinical Programme Lead, CRO client

Fifteen working days turnaround was quoted and met on every batch across a six-month study. No slippage, no surprises in the final report.

Dr. Michael PetherbridgeAlderley Edge · Study Director, a UK-based biotech

Inspections and standards

Questions sponsors ask

Is your laboratory MHRA GLP inspected, and when was the last inspection?

We're a member of the MHRA GLP Compliance Programme and are subject to periodic inspection against the OECD Principles of Good Laboratory Practice. Our most recent inspection was in March 2025; inspection history and status is available to prospective sponsors on request.

What guideline do you validate bioanalytical methods against?

Method validation follows ICH M10 (2022), the current internationally harmonised bioanalytical method validation guideline, adopted by MHRA, EMA and FDA. It replaced the previously separate EMA and FDA guidances, and is the standard we apply across every method regardless of which agency the study ultimately reports to.

How is your QA function kept independent of study conduct?

Our QA unit reports to the Managing Director, entirely outside the study director and analytical team's line management, in line with GLP principles. QA audits protocol, raw data and the final report at defined milestones and can raise a finding without needing sign-off from the study team.

Do you hold a Human Tissue Authority licence?

No, our routine bioanalytical work handles blood, plasma, urine and similar matrices, which fall outside the scope of material requiring an HTA licence. Where a study involves a tissue type that would bring it into HTA scope, we assess and advise on the applicable licensing on a study-by-study basis before accepting the work.

New study

Discuss a study with the study director.

Find us
Alderley Park Bioscience Campus, Alderley Park, SK10 4TR
Hours
Mon–Thu 08:00–18:00Fri 08:00–17:00Sat–Sun Closed